ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg/vial - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe initial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 30 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 45 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

ישראל - עברית - Ministry of Health

medici ltd - diphtheria toxoid 2 iu / 0.5 ml; poliomyelitis virus type 1 40 du/dose - suspension for injection - diphtheria-poliomyelitis-tetanus - this combined vaccine is indicated for adults as a booster of a previous vaccination for the simultaneous prevention of diphtheria tetanus and poliomyelitis. refer to the official recommendations for vaccination schedules. this vaccine may be administered as a booster of a previous vaccination to children 6 or older in exceptional cases particularly in the case of a shortage of the diphtheria tetanus and poliovirus vaccine (dtpolio) recommended in the vaccination schedule.

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).